Combined Delivery of a Lipopolysaccharide-Binding Peptide and the Heme Oxygenase-1 Gene Using Deoxycholic Acid-Conjugated Polyethylenimine for the Treatment of Acute Lung Injury

Ji Yeon Kim, Chunxian Piao, Gyeungyun Kim, Seonyeong Lee, Min Sang Lee, Ji Hoon Jeong, Minhyung Lee

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A ternary complex comprising plasmid DNA, lipopolysaccharide-binding peptide (LBP), and deoxycholic acid-conjugated polyethylenimine (PEI-DA) is prepared for combinational therapy of acute lung injury (ALI). The LBP is designed as an anti-inflammatory peptide based on the lipopolysaccharide (LPS)-binding domain of HMGB-1. In vitro cytokine assays show that LBP reduces levels of proinflammatory cytokines by inhibiting LPS. PEI-DA is synthesized as the gene carrier by conjugation of deoxycholic acid to low-molecular weight polyethylenimine (2 kDa, PEI2k). PEI-DA has higher transfection efficiency than high-molecular weight polyethylenimine (25 kDa, PEI25k). The ternary complex of an HO-1 plasmid (pHO-1), PEI-DA, and LBP is prepared as a combinational system to deliver the therapeutic gene and peptide. The transfection efficiency of the ternary complex is higher than that of the pHO-1/PEI-DA binary complex. The ternary complex also reduces TNF-α secretion in LPS-activated Raw264.7 macrophage cells. Administration of the ternary complex into the lungs of an animal ALI model by intratracheal injection induces HO-1 expression and reduces levels of proinflammatory cytokines more efficiently than the pHO-1/PEI-DA binary complex or LBP alone. In addition, the ternary complex reduces inflammation in the lungs. Therefore, the pHO-1/PEI-DA/LBP ternary complex may be an effective treatment for ALI. (Figure presented.).

Original languageEnglish
Article number1600490
JournalMacromolecular Bioscience
Volume17
Issue number8
DOIs
StatePublished - 2017 Aug 1

Fingerprint

Polyethyleneimine
Heme Oxygenase-1
Deoxycholic Acid
Acute Lung Injury
Polyetherimides
Peptides
Lipopolysaccharides
Genes
Acids
Therapeutics
Cytokines
Transfection
Molecular weight
HMGB Proteins
Plasmids
Molecular Weight
Oxygenases
Macrophages
Assays
Animals

Keywords

  • acute lung injury
  • anti-inflammation
  • gene delivery
  • heme oxygenase-1
  • lipopolysaccharide-binding peptide

Cite this

@article{48de2b2094da4ce1b399cb3109d39430,
title = "Combined Delivery of a Lipopolysaccharide-Binding Peptide and the Heme Oxygenase-1 Gene Using Deoxycholic Acid-Conjugated Polyethylenimine for the Treatment of Acute Lung Injury",
abstract = "A ternary complex comprising plasmid DNA, lipopolysaccharide-binding peptide (LBP), and deoxycholic acid-conjugated polyethylenimine (PEI-DA) is prepared for combinational therapy of acute lung injury (ALI). The LBP is designed as an anti-inflammatory peptide based on the lipopolysaccharide (LPS)-binding domain of HMGB-1. In vitro cytokine assays show that LBP reduces levels of proinflammatory cytokines by inhibiting LPS. PEI-DA is synthesized as the gene carrier by conjugation of deoxycholic acid to low-molecular weight polyethylenimine (2 kDa, PEI2k). PEI-DA has higher transfection efficiency than high-molecular weight polyethylenimine (25 kDa, PEI25k). The ternary complex of an HO-1 plasmid (pHO-1), PEI-DA, and LBP is prepared as a combinational system to deliver the therapeutic gene and peptide. The transfection efficiency of the ternary complex is higher than that of the pHO-1/PEI-DA binary complex. The ternary complex also reduces TNF-α secretion in LPS-activated Raw264.7 macrophage cells. Administration of the ternary complex into the lungs of an animal ALI model by intratracheal injection induces HO-1 expression and reduces levels of proinflammatory cytokines more efficiently than the pHO-1/PEI-DA binary complex or LBP alone. In addition, the ternary complex reduces inflammation in the lungs. Therefore, the pHO-1/PEI-DA/LBP ternary complex may be an effective treatment for ALI. (Figure presented.).",
keywords = "acute lung injury, anti-inflammation, gene delivery, heme oxygenase-1, lipopolysaccharide-binding peptide",
author = "Kim, {Ji Yeon} and Chunxian Piao and Gyeungyun Kim and Seonyeong Lee and Lee, {Min Sang} and Jeong, {Ji Hoon} and Minhyung Lee",
year = "2017",
month = "8",
day = "1",
doi = "10.1002/mabi.201600490",
language = "English",
volume = "17",
journal = "Macromolecular Bioscience",
issn = "1616-5187",
number = "8",

}

Combined Delivery of a Lipopolysaccharide-Binding Peptide and the Heme Oxygenase-1 Gene Using Deoxycholic Acid-Conjugated Polyethylenimine for the Treatment of Acute Lung Injury. / Kim, Ji Yeon; Piao, Chunxian; Kim, Gyeungyun; Lee, Seonyeong; Lee, Min Sang; Jeong, Ji Hoon; Lee, Minhyung.

In: Macromolecular Bioscience, Vol. 17, No. 8, 1600490, 01.08.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Combined Delivery of a Lipopolysaccharide-Binding Peptide and the Heme Oxygenase-1 Gene Using Deoxycholic Acid-Conjugated Polyethylenimine for the Treatment of Acute Lung Injury

AU - Kim, Ji Yeon

AU - Piao, Chunxian

AU - Kim, Gyeungyun

AU - Lee, Seonyeong

AU - Lee, Min Sang

AU - Jeong, Ji Hoon

AU - Lee, Minhyung

PY - 2017/8/1

Y1 - 2017/8/1

N2 - A ternary complex comprising plasmid DNA, lipopolysaccharide-binding peptide (LBP), and deoxycholic acid-conjugated polyethylenimine (PEI-DA) is prepared for combinational therapy of acute lung injury (ALI). The LBP is designed as an anti-inflammatory peptide based on the lipopolysaccharide (LPS)-binding domain of HMGB-1. In vitro cytokine assays show that LBP reduces levels of proinflammatory cytokines by inhibiting LPS. PEI-DA is synthesized as the gene carrier by conjugation of deoxycholic acid to low-molecular weight polyethylenimine (2 kDa, PEI2k). PEI-DA has higher transfection efficiency than high-molecular weight polyethylenimine (25 kDa, PEI25k). The ternary complex of an HO-1 plasmid (pHO-1), PEI-DA, and LBP is prepared as a combinational system to deliver the therapeutic gene and peptide. The transfection efficiency of the ternary complex is higher than that of the pHO-1/PEI-DA binary complex. The ternary complex also reduces TNF-α secretion in LPS-activated Raw264.7 macrophage cells. Administration of the ternary complex into the lungs of an animal ALI model by intratracheal injection induces HO-1 expression and reduces levels of proinflammatory cytokines more efficiently than the pHO-1/PEI-DA binary complex or LBP alone. In addition, the ternary complex reduces inflammation in the lungs. Therefore, the pHO-1/PEI-DA/LBP ternary complex may be an effective treatment for ALI. (Figure presented.).

AB - A ternary complex comprising plasmid DNA, lipopolysaccharide-binding peptide (LBP), and deoxycholic acid-conjugated polyethylenimine (PEI-DA) is prepared for combinational therapy of acute lung injury (ALI). The LBP is designed as an anti-inflammatory peptide based on the lipopolysaccharide (LPS)-binding domain of HMGB-1. In vitro cytokine assays show that LBP reduces levels of proinflammatory cytokines by inhibiting LPS. PEI-DA is synthesized as the gene carrier by conjugation of deoxycholic acid to low-molecular weight polyethylenimine (2 kDa, PEI2k). PEI-DA has higher transfection efficiency than high-molecular weight polyethylenimine (25 kDa, PEI25k). The ternary complex of an HO-1 plasmid (pHO-1), PEI-DA, and LBP is prepared as a combinational system to deliver the therapeutic gene and peptide. The transfection efficiency of the ternary complex is higher than that of the pHO-1/PEI-DA binary complex. The ternary complex also reduces TNF-α secretion in LPS-activated Raw264.7 macrophage cells. Administration of the ternary complex into the lungs of an animal ALI model by intratracheal injection induces HO-1 expression and reduces levels of proinflammatory cytokines more efficiently than the pHO-1/PEI-DA binary complex or LBP alone. In addition, the ternary complex reduces inflammation in the lungs. Therefore, the pHO-1/PEI-DA/LBP ternary complex may be an effective treatment for ALI. (Figure presented.).

KW - acute lung injury

KW - anti-inflammation

KW - gene delivery

KW - heme oxygenase-1

KW - lipopolysaccharide-binding peptide

UR - http://www.scopus.com/inward/record.url?scp=85019479108&partnerID=8YFLogxK

U2 - 10.1002/mabi.201600490

DO - 10.1002/mabi.201600490

M3 - Article

C2 - 28508430

AN - SCOPUS:85019479108

VL - 17

JO - Macromolecular Bioscience

JF - Macromolecular Bioscience

SN - 1616-5187

IS - 8

M1 - 1600490

ER -